reason report
price headwind biosimilar eros emerg despit
bottom line yesterday report result beat
consensu estim revenu earn
larg line above-consensu forecast despit
solid result see enough valuat upsid recommend
stock given signific headwind face portfolio
aimovig great start repatha may yet becom meaning
contributor sale pipelin emerg product
either small distant move needl valuat
quarter total revenu
consensu estim
result boost one-tim item aimovig mileston
account adjust enbrel product revenu miss
consensu oper margin line expect
share repurchas quarter drove posit
pro forma earn growth beat consensu
miss estim underscor
perform medium long term growth outlook compani
uncertain given emerg challeng biosimilar launch
neulasta epogen eros aranesp
increas competit challeng enbrel lower net price
growth driver repatha aimovig unclear us whether
launch aimovig support gener free good
program continu growth xgeva prolia hand
nich product off-set eros compar peer pharma
earli stage product candid still far proof-of-
concept let alon commerci success base quarter result
manag comment make modest chang
revenu forecast lower ep estim
chang chang peer
compani multipl maintain price target reiter
market perform rate stock
net debt total capit
price-to-earnings lt ep growth
averag dcf price-to-earnings p/sale
compani inform leerink partner llc research
revenu million dilut non-gaap ep
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
price target inc stock rate market perform
one first gener pioneer biopharmaceut industri succeed
basi build three massiv revenu pillar legaci product era three
product franchis epo epogen aranesp gcsf neulasta enbrel
face array brand gener competitor mean associ
revenu total like steadili declin offset outlook
number recent develop acquir product growth profit potenti
view unlik match legaci brand least mani year amgen
manag respond challeng restructur compani expens base
initi dividend lever compani balanc sheet cash trap off-shore
gener make legaci product compar peer regard
defens stock also one lack explos upsid potenti typic associ
breakthrough rapidli grow biotherapeut stock
total revenu grow slowli price volum pressur affect mani product
total revenu consensu
estim product sale grew yoy declin compar
result howev total revenu beat primarili contribut revenu
includ substanti un-model mileston payment partner novarti aimovig
collabor total product sale miss consensu estim
yoy volum growth off-set price headwind product beat
consensu sensipar contribut beat consensu vs lp thank
delay expect gener entri seem unlik persist product sale
drag prolia vs consensu vs lp kyproli vs consensu
vs lp repatha vs consensu vs lp recent launch biosimilar
neulasta appear taken toll neulasta us sale lead yoy qoq
eros enbrel sale came consensu estim
yoy declin enbrel sale mainli driven volum declin benefit
favor account adjust continu lose ground biosimilar
yoy qoq declin us sale among mani product kyproli neulasta
epogen sensipar repatha unit growth outpac sale growth sale declin
faster unit reflect trend slightli declin price across much portfolio
oper margin declin favor tax rate share repurchas propel ep growth
gross margin miss consensu estim lower prior
period potenti due lower net price repatha free drug suppli aimovig
 expens grew yoy sequenti sg expens increas year
ago repres total product sale sg grow faster revenu
appear compani increas commerci invest competit
intens payer scrutini product increas also launch aimovig
requir up-front invest overal oper margin stay strong although
notch lower period last year preced quarter tax rate
quarter non-gaap ep came repres growth yoy
repurchas share common stock total cost quarter reduc
dilut share count compar end compani still
remain stock repurchas author plan continu
opportunist share repurchas year
revenu ep guidanc rais modestli rais total revenu guidanc
full year previous guidanc rais
due perform date still reflect uncertainti potenti sensipar gener
competit outcom compani maintain guidanc tax rate rang
basi non- basi guidanc ep
narrow guidanc non-gaap ep
increas compani expect capit expenditur
year approxim lower previou guidanc
aimovig show strong launch trajectori despit free drug heavi discount
first-in-class cgrp receptor antibodi amgen aimovig approv fda may
expect analyst investor potenti growth driver us sale first full
quarter launch aimovig announc five month us
market patient start aimovig differ prescrib line
bullish thesi class see note littl headach robust
aimovig trend point blockbust class importantli disclos aimovig
payer-approv rate assuag investor concern major
aimovig prescript free sampl would readili convert pay
customers/pay though caution initi launch trajectori aid
bolu pent-up demand prescript growth trend moder go forward
compani believ applic patient awar aimovig suggest larg
opportun continu market expans address first dtc
advertis cgrp class although recent announc express script cover
aimovig emgal exclud ajovi mark formulari win lilli
associ total discount pay gain access probabl also limit overal
market potenti lilli offer refund list price drug
patient stop treatment within day see colleagu note
consid free drug suppli month three compani offer
expect disloc sale number stronger prescript trend continu
near futur
biosimilar eros neulasta underway threat recent approv
biosimilar version neulasta fulphila start take toll neulasta
us sale declin yoy sequenti disclos volum declin smaller
sale drop indic might proactiv lower neulasta price prepar
biosimilar entri nonetheless share onpro neulasta us sale declin
first time suggest mayb onpro user switch
biosimilar compani expect sever biosimilar neulasta approv
end neulasta sale pressur
pipelin laden earli stage molecul catalyst pipelin
signific gap market product typic broad portfolio earli stage asset
end year data expect phase ii poc studi
antibodi migrain prevent phase trial bcma bite
bite although shown encourag preliminari result small cohort
patient relapsed/refractori multipl myeloma potenti earli stage
bite remain valid larger proof-of-concept trial none present
earli stage studi seem like move stock affect investor sentiment expect
curious manag comment outlook even confid
likelihood approv call although bla even re-submit fda
back juli
modest model updat above-consensu forecast pt unchang base
quarter result manag comment increas revenu forecast slightli
follow year revenu forecast remain recent
consensu throughout forecast oper expens also increas
ep estim lower littl chang ep
forecast consensu chang chang
peer compani multipl price target remain reiter market
perform rate
price target inc base averag three approach
believ reason basi valu stock today approach simpl price
earn multipl larg cap us eu larg cap biopharma stock sni
rhhbi gsk nv price sale multipl larg cap biotechnolog pharma
compani novo discount cash flow dcf use rel multipl
larg cap biopharma compani ep appli ep
estim give one year futur valu use establish larg cap
futur revenu multipl sale appli revenu forecast amgen
give futur valu final dcf valuat base current
outlook compani exist product probability-weight revenu contribut
late stage pipelin program discount compani wacc give
fair valu today averag three approach give price target
risk view outlook valuat includ major chang label
price reimburs coverag compani legaci product failur
compani growth portfolio achiev futur sale forecast risk includ develop
delay disappoint earlier stage pipelin asset earlier signific eros
compani legaci product biosimilar innov competit shortfal
compani effort improv oper margin would also materi affect outlook
valuat would larg dilut acquisit therapeut area platform
sale
interest expens incom net
non-gaap incom tax
share count period basic
share count period dilut
guidanc
leerink partner research compani file zack factset consensu
leerink partner research compani file zack factset consensu
time
fda accept bla
leerink partner research compani report present clinicaltri gov
late stage pipelin program includ
late stage pipelin program exclud
million
corp partner revenue incl royalti
po probabl success fda approv
leerink partner research compani file
million
sale
total expens exclud revenue sharing/incl sg
 total revenu
sg total revenu excl profit share
profit share total revenu
leerink partner research compani file
analysi stock price leerink target
method model larg cap healthcar growth stock ep multipl
ep appli amgen ep
leerink updat ep estim
current averag ep multipl consensu ep
compar slow grow us eu larg cap biopharma
impli target price ep
revenu multipl appli leerink revenu forecast
leerink updat revenu estim
current averag larg cap biopharma multipl revenu
impli valu fy revenu
impli target price ep use us pharma compar
method dcf adjust debt declin flow
stabl termin cash flow growth discount
present valu flow termin valu
averag method
leerink partner research compani file factset
